Total Funding
33
Total FundingSeries C raised
Growth Score
pts
Heat Score
-7 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
78820
ReViral is a biotechnology company that develops and offers antiviral therapies for patients.
- Stuart Cockerill: Founder and Chief Scientific Officer
Ken Powell: Executive Chairman of the Board
Pfizer
About the Company
ReViral is a developer of antiviral drugs designed to help patients and enlarge the antiviral market by developing novel first-in-class compounds. The company's antiviral drugs is a fusion inhibitor of RSV which is a highly potent, novel small molecule and is being developed to treat RSV in patients with severe disease including neonates,
enabling patients to be treated who are infected with respiratory syncytial virus (RSV) by developing novel compounds.
